CDC Lowers Age for Pneumococcal Vaccination from 65 to 50
Lowering the age gives more adults the opportunity to protect themselves from pneumococcal disease at an age when the risk of infection increases, according to the CDC.
Lowering the age gives more adults the opportunity to protect themselves from pneumococcal disease at an age when the risk of infection increases, according to the CDC.
Lowering the age gives more adults the opportunity to protect themselves from pneumococcal disease at an age when the risk of infection increases, according to the CDC.
Read MoreThe phase 3 trial was investigating the vibostolimab and pembrolizumab combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Read MoreThe trial showed that clesrovimab reduced RSV-related respiratory infections in infants through day 150.
Read MoreA new RNA-based vaccine approved by the USDA offers protection against the year-round threat of canine influenza.
Read MoreThe vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older.
Read MoreThe injection on top of background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone.
Read MoreThe FDA accepted for priority review a new Biologics License Application for V116, Merck’s investigational 21-valent pneumococcal conjugate vaccine designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
Read MoreResearchers identified unusual COVID-19 mutation patterns that were strongly associated with molnupiravir use and coincided with the drug’s introduction.
Read MoreThe FDA approved an expanded indication for Merck’s Ervebo vaccine, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
Read MoreMerck’s investigational drug for chronic cough is one step closer to coming to market after receiving a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read MoreWith these approvals, healthcare professionals now have the option to administer Merck’s measles, mumps, rubella, and varicella vaccines intramuscularly.
Read MoreThe US Food and Drug Administration has accepted Merck’s new supplemental Biologics License Application based on data from the trial.
Read MoreThe FDA has expanded the approval for Merck’s Vaxneuvance for prevention of invasive disease caused by Streptococcus pneumoniae to include children 6 weeks through 17 years of age.
Read MoreThe FDA issued emergency authorization for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in adults age 18 and older with positive results of direct SARS-CoV-2 viral testing.
Read MoreThe European Commission approved Merck’s VaxNeuvance (Pneumococcal 15-valent Conjugate Vaccine) for prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
Read MoreExperts say the success of COVID Antiviral Pills depends on whether high-risk patients will be able to get tested, and then treated, fast enough to make a difference.
Read MoreMerck has entered into a voluntary licensing agreement to allow the production of its investigational COVID-19 antiviral molnupiravir by drugmakers in 105 low- and middle-income countries.
Read MoreMerck’s COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50% compared to placebo.
Read MoreThe FDA approved a new pneumonia vaccine from Merck, according to a report from the Boston Herald.
Read MoreMerck KGaA’s experimental lung cancer treatment bintrafusp alfa failed in an early trial, the company recently announced.
Read MoreTwo Phase 3 studies of Merck’s investigational 15-valent pneumococcal conjugate vaccine met their primary immunogenicity objectives.
Read More“Because of the risk of mental health side effects, the benefits of montelukast may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with other medicines,” the FDA said.
Read MoreThe FDA says Novartis and Merck have jointly decided to voluntarily discontinue manufacture of Foradil Aerolizer “for business reasons.”
Read MoreThe FDA has approved Ragwitek, a sublingual allergen extract to treat short ragweed pollen induced allergic rhinitis (hay fever) in adults 18 years through 65 years of age.
Read More